A phase i clinical trial of novel anticancer drug dicycloplatin in patients with advanced solid malignancies

• In: Hospital Pharmacy Section - Posters
• At: Beijing (China) (2007)
• Type: Poster
• Poster code: HPS-P-043
• By: YANG, Xu-qing (Beijing Xingda Pharmaceutical, Inc., Beijing, China)
• Co-author(s): Guan, Zhong-zhen (Cancer Hospital of Sun YatSen University, GUANGZHOU, China)
  Li, Su (Cancer Hospital of Sun YatSen University, GUANGZHOU, China)
  Yang, Zhen-yun (Beijing Xingda Pharmaceutical, Inc., BEIJING, China)
  Cui, Wei-Chuan (Beijing Xingda Pharmaceutical, Inc., BEIJING, China)
  Liu, Chang-nian (Beijing Xingda Pharmaceutical, Inc., BEIJING, China)
  
• Abstract:

  OBJECTIVE The main objectives of this phase I and pharmacokinetic study were to characterize the principal toxicities and determine the maximum tolerated dose (MTD)of dicycloplatin. The study also sought to determine the recommended dose for phase II trials of dicycloplatin and detect preliminary evidence of antitumor activity in patients with ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login